A Phase 1a/1b, Dose-Ranging Study of the Safety, Tolerability, Pharmacokinetics, and Initial Efficacy of ABI-H0731 in Healthy Volunteers and Patients With Chronic Hepatitis B
Phase of Trial: Phase I
Latest Information Update: 09 Jul 2017
At a glance
- Drugs ABI-H0731 (Primary) ; Entecavir; Tenofovir dipivoxil fumarate
- Indications Hepatitis B
- Focus Adverse reactions
- Sponsors Assembly Biosciences
- 24 May 2017 Planned End Date changed from 1 Dec 2017 to 1 Apr 2018.
- 24 May 2017 Planned primary completion date changed from 1 Aug 2017 to 1 Dec 2017.
- 14 Mar 2017 Status changed from not yet recruiting to recruiting.